Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Jun 9 · inside the Ichimoku cloud · RSI 47 · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in NSTM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NSTM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NSTM.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 100.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 300.0 | -25.0 | -33.3 | 0.0 | 50.0 | -33.3 | 0.0 | -50.0 | 0.0% |
| 2024 | 33.3 | -25.0 | 16.7 | -14.3 | 0.0 | 16.7 | -14.3 | 0.0 | -33.3 | -75.0 | 0.0 | 0.0 | −83.3% |
| 2023 | -5.3 | 11.1 | 0.0 | 0.0 | 0.0 | 10.0 | 4.5 | 4.3 | -25.0 | -33.3 | -33.3 | -25.0 | −68.4% |
| 2022 | 3.6 | 0.0 | -13.8 | 8.0 | 3.7 | -32.1 | 15.8 | -13.6 | -15.8 | 12.5 | 0.0 | 5.6 | −32.1% |
| 2021 | -5.0 | 26.3 | 12.5 | -14.8 | 52.2 | -17.1 | -3.4 | -28.6 | 50.0 | 3.3 | 0.0 | -9.7 | +40.0% |
| 2020 | 11.1 | 20.0 | -16.7 | -10.0 | -11.1 | 0.0 | -12.5 | 0.0 | 0.0 | 0.0 | 0.0 | 185.7 | +122.2% |
| 2019 | 0.0 | 50.0 | -25.0 | -11.1 | 25.0 | 0.0 | 0.0 | -20.0 | -25.0 | 16.7 | 0.0 | 28.6 | +12.5% |
| 2018 | -12.5 | 6.3 | 4.5 | -70.0 | -4.8 | 0.0 | -10.0 | 0.0 | -11.1 | -31.2 | -9.1 | -20.0 | −88.9% |
| 2017 | 3.8 | 1.2 | -8.5 | 6.7 | 0.0 | -6.3 | 0.0 | -6.7 | -7.1 | 20.0 | -6.4 | -1.4 | −7.7% |
| 2016 | -23.5 | 34.6 | -12.9 | 6.6 | 7.7 | -17.1 | 3.4 | -5.0 | 28.1 | 0.0 | 12.3 | -4.9 | +14.7% |
| 2015 | -22.2 | -6.5 | -2.8 | 2.9 | 5.6 | -7.9 | 1.4 | -7.0 | 9.1 | -4.2 | 1.4 | -2.9 | −31.3% |
| 2014 | 0.7 | -5.7 | 9.0 | -13.8 | 0.0 | 12.0 | -10.0 | 7.9 | -5.9 | -13.3 | -2.7 | -8.3 | −29.3% |
| 2013 | -2.2 | 0.0 | -5.3 | 10.4 | 4.3 | -6.9 | -3.7 | 33.3 | -2.9 | 13.2 | -21.7 | -5.4 | +3.7% |
| 2012 | -2.4 | -10.5 | -3.6 | 2.8 | 14.5 | -2.4 | 3.3 | -0.8 | 14.3 | -3.5 | -1.4 | -1.5 | +6.3% |
| 2011 | 17.7 | -14.5 | 7.9 | -4.5 | -5.3 | -8.7 | 9.5 | -2.5 | -5.1 | -13.4 | 0.8 | -2.3 | −22.6% |
| 2010 | -5.0 | -6.8 | -4.8 | 0.0 | 1.7 | -1.7 | -3.4 | -7.0 | 11.3 | 6.8 | 20.6 | 7.9 | +17.1% |
| 2009 | -2.0 | -28.6 | 28.6 | 6.7 | 46.9 | 11.3 | 1.3 | 0.6 | -5.6 | -0.7 | -26.7 | 27.3 | +40.0% |
| 2008 | -3.1 | -5.3 | -9.0 | 7.4 | -5.8 | 0.8 | -2.0 | 13.2 | -17.9 | -9.3 | -50.5 | -1.0 | −65.5% |
| 2007 | -1.9 | 8.0 | -1.3 | 7.7 | -7.4 | -0.5 | -9.6 | -6.1 | -4.6 | -1.1 | -23.8 | 9.0 | −31.0% |
No analyst coverage for this instrument.
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
No recent headlines.